世界中医药2017，Vol.12Issue(2)：258-265,8.DOI:10.3969/j.issn.1673-7202.2017.02.006
丹红注射液干预择期PCI围手术期心肌保护与安全性的系统评价
Danhong Injection for Periprocedural Myocardical Injury in Elective Percutaneous Coronary:A Systemactic Review
摘要
Abstract
Objective:To observe the protective effect and safety of Danhong Injection (DHI) in combination with western medicine for PMI following elective PCI through systematic review.Methods:A systematic review of RCTs of DHI for the treatment and prevention of PMI following elective PCI were conducted on the basis of Cochrane,Medline,CNKI,VIP,CMCI and Wanfang.Data included the founding year to 31 Jan,2017.Two researchers independently selected the articles and extracted data.Then the quality was assessed and results cross-cheecked.Revman 5.3 was used in the analysis of the results.Results:Eleven RCTs that enrolled 956 patients were included.All were conducted in China.The control group(C,471 cases) was given conventional western medicine,and treatment group(T,485 cases) was given Danhong injection on that basis.It implies that,1) Danhong Injection can decrease the occurrence of myocardial infarction.2) After PCI 24hr,Danhong Injection can lower down CK-MB level with statistical difference [MD=-6.46,95%CI (-8.57,-4.34),Z=5.99,P<0.00001];and the level of cTNI,with statistical difference [SMD=-0.36,95%CI(-0.68,-0.03),Z=2.16,P=0.03].3)After PCI 24hr,it can reduce the level of hs-CRP [SMD=-0.53,95%CI(-0.70,-0.35),6.02,P<0.00001] and the level of IL-6,[SMD=-0.66,95%CI (-0.92,-0.40),Z=5.02,P<0.00001] with statistical significance.4) It can increase the level of SOD and decrease that of MDA.5) Decrease the level of ET.6) Decrease occurrence of cardiovascular disease without inducing further adverse reactions.Conclusion:DHI might be a potentially efficacious treatment of PMI following elective PCI.Nevertheless,its safety remains uncertain because of limited information.Owing to the fact that the overall quality of the studies was low,higher qualified RCTs are expected.关键词
丹红注射液/PCI围手术期心肌损伤/心肌保护/随机对照试验/系统评价Key words
Danhong injection/Perioperative myocardial injury (PMI)/Randomized controlled trial/Systematic review分类
医药卫生引用本文复制引用
张玉灵,尚菊菊,邢文龙,李享,周琦,来晓磊,杨志海,刘红旭..丹红注射液干预择期PCI围手术期心肌保护与安全性的系统评价[J].世界中医药,2017,12(2):258-265,8.基金项目
首都卫生发展科研专项-重点攻关项目(编号:首发2014-1-2231) （编号:首发2014-1-2231）
北京市中医药管理局重点学科项目 （）
合作建立步长脑心同治重点实验室 （）
